CN Patent

CN115397424A — 人类免疫缺陷病毒复制的抑制剂

Assigned to ViiV Healthcare UK No 5 Ltd · Expires 2022-11-25 · 3y expired

What this patent protects

本申请记载了包含式Ia、式Ib、式Ic、或式Id的化合物、或它们药学上可接受的盐的药物组合物。

USPTO Abstract

本申请记载了包含式Ia、式Ib、式Ic、或式Id的化合物、或它们药学上可接受的盐的药物组合物。

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CN115397424A
Jurisdiction: CN
Classification: —
Expires: 2022-11-25
Drug substance claim: No
Drug product claim: No
Assignee: ViiV Healthcare UK No 5 Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.